

# Duke Cancer Network and Duke Cancer Institute's 21<sup>st</sup> Annual Virtual Duke Debates



## Controversies in the Management of Patients with Hematologic Malignancies

Please register for the conference using the link below:

[https://duke.zoom.us/webinar/register/WN\\_SjwJgHb3T-aSS\\_Yg5CjbPQ](https://duke.zoom.us/webinar/register/WN_SjwJgHb3T-aSS_Yg5CjbPQ)

### Program Description:

This annual event brings together experts in hematologic malignancies to debate and discuss advances in treatments, novel treatment options, and current treatment paradigms.

### Target Audience:

This educational activity is designed for medical oncologists, hematologists, radiation oncologists, surgical oncologists, pharmacists, nurse practitioners, physician assistants, fellows, nurses and other health care professionals interested in the treatment of patients with hematologic malignancies.


### Learning Objectives:

- Describe emerging data and recent advances in the management of malignant and benign hematologic disease
- Compare traditional and emerging treatment options in the management of hematologic disease
- Examine the management of acute and late toxicities of CAR-T and immune therapies

### Debates:

- All Patients Over the Age of 60 with AML Should Have Induction Therapy with Targeted Agents (Ven/HMA; Glasdegib/HMA; or similar approach) Rather Than Standard 7 plus 3!
- AYA Patients with BCR/ABL Negative ALL Should Receive a Pediatric Inspired Regimen and Reserve allo HSCT for Management of Relapse
- PV Patients Can be Adequately Managed Through the Entire Course of Their Disease with Aspirin, Phlebotomy, Hydroxyurea and/or Interferon
- Radiation Therapy Alone is the Preferred Management for Stage 1 Mantle Cell Lymphoma
- Venetoclax should be used frontline in CLL before Ibrutinib
- Patients with relapsed mantle cell lymphoma should receive CAR-T therapy rather than traditional re-induction therapy and transplantation
- CAR-T and Immune Therapies Management of Acute and Late Toxicities - What the community provider needs to know
- The Role of Molecular Tumor Board in Heme Malignancies and how Duke can support you!
- Sickle Cell Topic: "Novel/New Therapies Are Worth It!"

August  
14



Friday,  
August 14, 2020  
8:00-5:15

**Presented by:**  
*Duke Cancer Network in  
collaboration with Duke Cancer  
Institute*



**DukeHealth**

For additional information contact  
Beth Tanner at [beth.tanner@duke.edu](mailto:beth.tanner@duke.edu)